Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection


23 Nov 2019


Poster display session


Tumour Site

Small Cell Lung Cancer


Weigang Xiu


Annals of Oncology (2019) 30 (suppl_9): ix157-ix181. 10.1093/annonc/mdz437


W. Xiu1, Y. Huang1, X. Zhou1, L. Zhou1, J. Xue1, J. Zhu1, M. Huang2, F. Peng1, Y. Liu1, Y. Xu1, Y. Zhang1, M. Yu2, Y. Li1, Y. Wang2, Y. Lu2, Y. Gong1

Author affiliations

  • 1 Department Of Thoracic Oncology And State Key Laboratory Of Biotherapy, Cancer Center, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 2 Department Of Thoracic Oncology, West China Hospital of Sichuan University, 610041 - Chengdu/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 523P


The aim of this study was to investigate the impact of main co-morbidities in China: hypertension, type 2 diabetes and chronic hepatitis B viral (HBV) infection on overall survival of patients with extensive-stage small-cell lung cancer (SCLC).


Between 2009 and 2018, patients with pathologically diagnosis of SCLC in our hospital were reviewed, and the extensive stage cases were recruited in present study. Patients were divided into hypertension and non-hypertension, diabetes and non-diabetes, HBV-positive and HBV-negative group. The overall survival (OS) was evaluated using the Kaplan-Meier method and Cox proportional hazard models in each group respectively. This work was approved by the West China Hospital Research Ethics Board.


Totally, 1345 SCLC patients were reviewed. 632 patients (46.9%) were confirmed with extensive-stage SCLC and analyzed. The median OS in present study was 14.6 months (95% confidence interval (CI) 13.8-15.4 months). The OS of patients with type 2 diabetes (median 17.3 months, 95% CI 14.9-19.8 months) and HBV infection (median 19.9 months, 95% CI 16.1-23.7 months) were significantly improved, comparing to the patients without diabetes (median 14.2 months, 95% CI 13.4-15.1 months) and HBV infection (median 14.2 months, 95% CI 13.4-15.0 months), respectively (p < 0.05). No significant difference in OS was observed in hypertension and non-hypertension group (median 15.7 vs. 14.4 months, p > 0.05). The prognosis significantly decreased if the patients with type 2 diabetes (HR = 0.78, 95% CI: 0.62-0.99, p = 0.046) and HBV infection (HR = 0.61, 95% CI: 0.45-0.83, p = 0.001), comparing to those patients without diabetes or HBV infection.


Present data indicated that the co-morbidities (type 2 diabetes and HBV infection) might be associated with the favorable prognosis in extensive-stage SCLC patients. Prospective studies are warranted to verify our findings.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.